Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:UNH

UnitedHealth Group Inc (UNH)

411.04
+2.52 (0.62%)
as of Jun 15, 2026, 8:00:00 pm Market Open.
287 watching
0
Investor Insights
star iconJun 14, 2026, 12:00 am

This summary was created by AI, based on 43 opinions in the last 12 months.

UnitedHealth Group Inc (UNH-N) has faced considerable challenges over the past year, reflected in its declining stock price and regulatory scrutiny. Experts note that while the company is fundamentally strong with significant vertical integration in the U.S. healthcare system, it has been impacted by rising medical costs, regulatory pressures, and changes in Medicare reimbursement rates. The new CEO’s leadership is viewed as a positive factor that could guide the company through its current difficulties, but many analysts express caution due to the speculative nature of recent issues and the stock's volatility. Some believe the downturn creates buying opportunities, suggesting that long-term growth may be achievable if operational concerns are resolved. Overall, the sentiment is mixed, with a few experts optimistic about potential recovery while others advise caution until more clarity emerges.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
Cvs, CVS
DON'T BUY

Buffett's very smart and can give you a reason to look at a stock. Catching a falling knife isn't his strategy. Turnaround will not be quick or smooth. He's avoided healthcare for the most part, owning just BSX.

BUY

He re-entered this, because the stock was moving up. Later, he realized it was because of Buffett buying it. The fundamentals alone are dead money. Expect it to hit $325 then pause. They won't resume growth till 2026.

BUY

He added more last week and today. The market wants momentum.

RISKY

Dark clouds are concern about overstated revenues plus current regulatory environment. If you want to invest in something and look like a hero a year from now, you could take a very small percentage. Taking on risk if something else blows up. Can't see a basing pattern yet.

Stock's PE is cheap, but he sees negative earnings growth over next few years. Reports of hedge fund companies getting in is a positive. Very oversold.

DON'T BUY

Numbers are fantastic, nothing wrong there. Potential fraud, being investigated. You can't quantify something like that. When he doesn't know, he has to step aside. There's already enough risk in the stock market when you buy the "perfect" company, and it can still go down 10%. He's willing to miss a bit of any upside and wait for a resolution to the story.

PAST TOP PICK
(A Top Pick Jan 27/25, Down 50%)

Nothing is too big to fail, but UNH is so integrated into the US healthcare system that they are an essential service. Problem is more people are getting utilization in areas that are higher cost. So, their estimates got blown out. Has long owned this. He recommended it for its multiyear consistent earnings. They just reported and are guiding resumption of growth in 2026. Is at a 35% discount to its 3-year forward earnings. He was buying this morning on their earnings call.

WAIT

It has had issues and it has been a tough year facing several challenges. Owns it in the global equity fund. He is waiting for the conference call tomorrow which should talk about how the issues are being dealt with. They have pulled their guidance on EPS and the new CEO could be putting out a new guidance level. Wait for the base line to grow but there is long term upside.

PAST TOP PICK
(A Top Pick Jul 17/24, Down 49%)

She averaged down and bought at $273 in May. Stock's been under a lot of pressure. Largest US healthcare manager, with strong vertical integration. Guidance cut, EPS outlook dropped. Under 11x forward PE despite 13-16% long-term target EPS growth. Sees ~25% upside from here.

COMMENT

It could be a long turnaround, though the CEO is the person who can turn it around. You need fortitude to be in this.

DON'T BUY

Really tough situation. When an insurance company falls on hard times, it's so difficult to analyze. How pervasive are the problems? Historically, quite a strong compounder. Lots of political pressure on insurance reimbursement. Steer clear for now.

COMMENT

Time will tell is they recover or not from the recent slide (shares fell by half). Their medical cost ratios have risen and we'll see if they maintain a higher level. There were fewer medical procedures during Covid, but has since increased, but also has pushed up costs for the insurers. But some issues may be temporary, including Medicare and Medicaid rates.

PAST TOP PICK
(A Top Pick Jul 17/24, Down 45%)

It is one of the most integrated companies in U.S. health care. They thought it was very oversold so they doubled down on their position and will trend back. She is looking for 13 to 16% long term upside but doesn't consider it a buy and hold. Should be a high quality compounder.

BUY

Despite being -39% this year, she is holding on and even buying more. UNH has fixable problems, being structural changes, starting with better Medicare/Medicaid reimbursement.

BUY

He bought it back and bought more today. Steady management. They made a mistake underwriting Humana. V28 is behind them. They will have a kitchen sink quarter and you can count on the guidance. It will rally.

Unspecified

There has been concern over paying nursing homes to not send patients to hospitals. He is not sure if this true but it raises caution. There is also concern over the U.S. trying to not pay claims. The U.S. administration is going after costs in health care and profits in PDM. There is likely more bad news coming out. After three years it should probably be OK.

Showing 31 to 45 of 285 entries